Abstract
New indications may soon exist for liothyronine [triiodothyronine; T3] and adenosine in the field of cardiovascular medicine. Preliminary success with these agents was reported at the 15th Annual Meeting of the Society of Cardiovascular Anesthesiologists, held in San Diego, US, last month.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have